BeneFIX is a recombinant factor IX, with no added human or animal plasma or albumin used in the manufacturing process.
Advancing Viral Safety
The only recombinant factor IX available to patients
BeneFIX is not derived from human blood and contains no preservatives or added animal or human components
- No human or animal proteins are added during the purification and formulation process of BeneFIX
- Chinese hamster ovary (CHO) cells used to manufacture BeneFIX are grown in media containing no added human or animal components
BeneFIX is a leader in recombinant therapy for hemophilia B, with over 12 years of experience*
*BeneFIX was approved February 11, 1997.
The manufacturing process for BeneFIX includes multiple purification steps
The production process is designed with viral safety in mind:
- Use of well-characterized CHO cells
- Extensive testing of production strain—shown to be free of known infectious agents
- A manufacturing process and formulation that does not use blood or plasma products
- A purification process that involves using multiple chromatography steps and nanofiltration